Researchers are preparing to recruit migraine sufferers for participation in a major phase II and III drug trial. The 17-week trial, sponsored by GlaxoSmithKline, will evaluate the effectiveness, tolerability, and safety of various doses of a new drug – GSK1838262 (XP13512) – as a means of preventing migraine.
The drug has been defined as a “novel prodrug of gabapentin” (Neurontin) – that is, a drug that is converted to gabapentin in the intestine – so as to be better absorbed and more bioavailable. (To read a discussion of XP13512 vs. gabapentin in the context of a trial in restless legs syndrome patients, click here.)
Target enrollment is 450 migraine patients 18 years and older suffering 3 or more headache attacks (migraine & non-migraine) per month but less than 15 total headache days in the preceding 3 months.
For more information, and to find the contact name and phone number at any of the 53 study locations, see the ClinicalTrials.gov listing for the “Prevention Study in Adult Patients Suffering from Migraine Headaches” and refer to ID number NCT00742209.